help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on December 10, 2004, doi:10.1164/rccm.200403-404OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200403-404OCv1
171/6/621    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodman, D. M.
Right arrow Articles by Nick, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodman, D. M.
Right arrow Articles by Nick, J. A.
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 621-626, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200403-404OC


Original Article

Late Diagnosis Defines a Unique Population of Long-term Survivors of Cystic Fibrosis

David M. Rodman, Jillian M. Polis, Sonya L. Heltshe, Marci K. Sontag, Cathy Chacon, Rachel V. Rodman, Sara J. Brayshaw, Gwen A. Huitt, Michael D. Iseman, Milene T. Saavedra, Lynn M. Taussig, Jeffrey S. Wagener, Frank J. Accurso and Jerry A. Nick

Cystic Fibrosis Center, The University of Colorado Health Sciences Center; National Jewish Medical and Research Center; The Children's Hospital, Denver, Colorado

Correspondence and requests for reprints should be addressed to David M. Rodman, M.D., Director, Center for Genetic Lung Disease, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262. E-mail: david.rodman{at}uchsc.edu

Although the median survival for patients with cystic fibrosis (CF) is 32.9 years, a small group of patients live much longer. We analyzed the genotype and phenotype of CF patients 40 years and older seen between 1992 and 2004 at the National Jewish Medical and Research Center (n = 55). These patients were divided into two groups according to age at diagnosis: an early diagnosis (ED) group, median age at diagnosis 2.0 years (range 0.1–15 years, n = 28), and a late diagnosis (LD) group, median age of diagnosis 48.8 years (range 24–72.8 years, n = 27). Consistent with the hypothesis that the CFTR genotype affects the age at diagnosis, CFTR {Delta}F508 homozygous individuals were more common in the ED group. Although patients in the ED group were predominantly male, the majority of LD patients were female. Patients with CF diagnosed late had a significantly lower prevalence of pancreatic insufficiency and CF-related diabetes, and better lung function. Fewer patients in the LD groups were infected with Pseudomonas aeruginosa, whereas a greater percentage had cultures positive for nontuberculous mycobacteria. This is the largest cohort of older patients with CF described to date, and our findings indicate that patients diagnosed as adults differ distinctly from survivors of long-term CF diagnosed as children.

Key Words: genotype • lung • mutation • Pseudomonas aeruginosa • nontuberculous mycobacteria • sweat chloride




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
E. C. Dasenbrook, C. A. Merlo, M. Diener-West, N. Lechtzin, and M. P. Boyle
Persistent Methicillin-resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 814 - 821.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
V. Scotet, M.-P. Audrezet, M. Roussey, G. Rault, A. Dirou-Prigent, H. Journel, V. Moisan-Petit, V. Storni, and C. Ferec
Immunoreactive Trypsin/DNA Newborn Screening for Cystic Fibrosis: Should the R117H Variant Be Included in CFTR Mutation Panels?
Pediatrics, November 1, 2006; 118(5): e1523 - e1529.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. K. Field and R. L. Cowie
Lung Disease Due to the More Common Nontuberculous Mycobacteria
Chest, June 1, 2006; 129(6): 1653 - 1672.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. J. Accurso
Update in cystic fibrosis 2005.
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 944 - 947.
[Full Text] [PDF]


Home page
Diabetes CareHome page
M. Creus, W. Vogel, and H. Zoller
Of Genes and Men: The Alternative View of Sex Differences in Cystic Fibrosis: Response to Sims et al. and Milla et al.
Diabetes Care, January 1, 2006; 29(1): 179 - 180.
[Full Text] [PDF]


Home page
Diabetes CareHome page
E. J. Sims, J. McCormick, and A. Mehta
Of Genes and Men: The Alternative View of Sex Differences in Cystic Fibrosis: Response to Creus et al.
Diabetes Care, January 1, 2006; 29(1): 180 - 181.
[Full Text] [PDF]


Home page
ThoraxHome page
V Cottin, Y Thibout, F Bey-Omar, I Durieu, L Laoust, Y Morel, and J-F Cordier
Late CF caused by homozygous IVS8-5T CFTR polymorphism
Thorax, November 1, 2005; 60(11): 974 - 975.
[Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
B D Callaghan, A F Hoo, R Dinwiddie, I M Balfour-Lynn, and S B Carr
Growth and lung function in Asian patients with cystic fibrosis
Arch. Dis. Child., October 1, 2005; 90(10): 1029 - 1032.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society
  ATS State of the Art Course 2008